바이오모아 (BioMoa) — ADC · Antibody

9268프로그램 35FDA 승인

0오늘 방문

738누적 방문

8122갱신 대기 S–CData Tier S/A/B차세대 1068HER2 breast 5456Antibody 2744CGT →Psoriasis →NSCLC 35FDA 승인

피드 Data Tier 차세대

최근 활동

RSS →

AntibodystalePfizerPhase 2

tanezumab (PF-04383119, PF-04383119 (tanezumab))

Osteoarthritis, Knee · Osteoarthritis, Knee

#OsteoarthritisKnee#Antibody#Phase2#항체#면역항체+4

임상시험 1상태 ACTIVE

AntibodystaleRochePhase 3

Bevacizumab-awwb (Bevacizumab-awwb)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleBeiGenePhase 2

Tislelizumab combined with chemotherapy (Tislelizumab combined with chemotherapy)

Rectal Cancer; Rectal Cancer Stage II · Rectal Cancer

#RectalCancer#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 RECRUITING

AntibodystaleGenzyme, a Sanofi CompanyPhase 2

alemtuzumab (CAMPATH, CAMPATH (alemtuzumab))

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 DISCONTINUED

AntibodystaleUniversity of LeicesterPhase 2

Dostarlimab and Niraparib (Dostarlimab and Niraparib)

Mesothelioma, Malignant · Mesothelioma, Malignant

#MesotheliomaMalignant#Antibody#Phase2#항체#면역항체+4

임상시험 1상태 ACTIVE

AntibodystaleRochePreclinical

Rituximab, Methotrexate, and Thiotepa (R-MT, Rituximab, Methotrexate, and Thiotepa, Rituximab, Methotrexate, and Thiotepa (R-MT) Induction Followed by Etoposide and Cytarabine (EA) Consolidation)

Primary Central Nervous System Lymphoma (PCNSL); CNS Lymphoma Treatment · Primary Central Nervous System Lymphoma

#PrimaryCentralNervousSystemLymph#Antibody#Preclinical#항체#면역항체+3

임상시험 1상태 RECRUITING

AntibodyBiologicstaleSWISS BIOPHARMA MED GmbHPhase 1

Monoclonal antibody (Mab, Monoclonal antibody, Monoclonal antibody (Mab) sB24M)

Pyoderma; Pyoderma Gangrenosum · Pyoderma

#Pyoderma#Antibody#Phase1#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleJohnson & Johnson Pharmaceutica…Phase 2

doxorubicin HCL liposome; bevacizumab; carboplatin (doxorubicin HCL liposome; bevacizumab; carboplatin)

Ovarian Neoplasms; Fallopian Tube Neoplasms · Ovarian Neoplasms

#OvarianNeoplasms#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleIsofol Medical ABPhase 2

ARFOX + bevacizumab (arfolitixorin, arfolitixorin (ARFOX + bevacizumab))

Metastatic Colorectal Cancer (mCRC) · Metastatic Colorectal Cancer (mCRC)

#MetastaticColorectalCancermCRC#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleEli Lilly and CompanyPhase 2

Ramucirumab DP (Ramucirumab DP)

Carcinoma of Urinary Tract; Urethral Carcinoma · Carcinoma of Urinary Tract

#CarcinomaofUrinaryTract#Antibody#Phase2#항체#면역항체+3

효능 ORR 28.8%임상시험 1상태 ACTIVE

AntibodystaleNational Cancer Center, KoreaPhase 2

Erlotinib plus Bevacizumab (Erlotinib plus Bevacizumab)

EGFR Positive Non-small Cell Lung Cancer · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleBristol Myers SquibbPhase 2

Ipilimumab and Fotemustine (Ipilimumab and Fotemustine)

Metastatic Malignant Melanoma · Metastatic Malignant Melanoma

#MetastaticMalignantMelanoma#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleKyntra BioPhase 2

Pamrevlumab (Pamrevlumab)

Idiopathic Pulmonary Fibrosis · Idiopathic Pulmonary Fibrosis

#IdiopathicPulmonaryFibrosis#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleZenas BioPharma (USA), LLCPhase 2

Obexelimab (Obexelimab)

Relapsing Multiple Sclerosis · Relapsing Multiple Sclerosis

#RelapsingMultipleSclerosis#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleAmgenApproved

Denosumab Prefilled Syringe [Prolia] (Denosumab Prefilled Syringe [Prolia])

Spine Deformity · Spine Deformity

#SpineDeformity#Antibody#Approved#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleElevation OncologyPhase 2

Seribantumab (Seribantumab)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 DISCONTINUED

AntibodystaleSun Yat-sen UniversityPhase 2

Sindilizumab (Sindilizumab)

Colorectal Cancer Metastatic; Chemotherapy · Colorectal Cancer Metastatic

#ColorectalCancerMetastatic#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 RECRUITING

AntibodystaleInnoventPhase 2

Sintilimab with Interleukin-2+CAPOX (Sintilimab with Interleukin-2+CAPOX)

Locally Advanced Rectal Adenocarcinoma · Locally Advanced Rectal Adenocarcinoma

#LocallyAdvancedRectalAdenocarcin#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleRochePhase 2

Bevacizumab and Bortezomib (Bevacizumab and Bortezomib)

Renal Cell Cancer · Renal Cell Cancer

#RenalCellCancer#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleCytoDyn, Inc.Preclinical

PRO 140 (leronlimab, leronlimab (PRO 140))

TNBC; TNBC - Triple-Negative Breast Cancer · TNBC

#TNBC#Antibody#Preclinical#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleKiniksa Pharmaceuticals Interna…Phase 3

mavrilimumab (mavrilimumab)

COVID · COVID

#COVID#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleAbbVie (prior sponsor, Abbott)Phase 3

Palivizumab (Palivizumab)

Respiratory Syncytial Virus Infection · Respiratory Syncytial Virus Infection

#RespiratorySyncytialVirusInfecti#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleHawaii Pacific HealthPhase 2

ranibizumab (Lucentis, high-dose ranibizumab)

PCV; Polypoidal Choroidal Vasculopathy · PCV

#PCV#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleAgendiaApproved

trastuzumab (Herceptin, T + trastuzumab followed by CEF + trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Approved#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleAgendiaApproved

trastuzumab (Herceptin, Dose dense AC followed by T + trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Approved#항체#면역항체+2

임상시험 1상태 ACTIVE

86 / 167 페이지

← 이전 다음 →

전체 9,268개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 0 / 738

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

tanezumab (PF-04383119, PF-04383119 (tanezumab))

Bevacizumab-awwb (Bevacizumab-awwb)

Tislelizumab combined with chemotherapy (Tislelizumab combined with chemotherapy)

alemtuzumab (CAMPATH, CAMPATH (alemtuzumab))

Dostarlimab and Niraparib (Dostarlimab and Niraparib)

Rituximab, Methotrexate, and Thiotepa (R-MT, Rituximab, Methotrexate, and Thiotepa, Rituximab, Methotrexate, and Thiotepa (R-MT) Induction Followed by Etoposide and Cytarabine (EA) Consolidation)

Monoclonal antibody (Mab, Monoclonal antibody, Monoclonal antibody (Mab) sB24M)

doxorubicin HCL liposome; bevacizumab; carboplatin (doxorubicin HCL liposome; bevacizumab; carboplatin)

ARFOX + bevacizumab (arfolitixorin, arfolitixorin (ARFOX + bevacizumab))

Ramucirumab DP (Ramucirumab DP)

Erlotinib plus Bevacizumab (Erlotinib plus Bevacizumab)

Ipilimumab and Fotemustine (Ipilimumab and Fotemustine)

Pamrevlumab (Pamrevlumab)

Obexelimab (Obexelimab)

Denosumab Prefilled Syringe [Prolia] (Denosumab Prefilled Syringe [Prolia])

Seribantumab (Seribantumab)

Sindilizumab (Sindilizumab)

Sintilimab with Interleukin-2+CAPOX (Sintilimab with Interleukin-2+CAPOX)

Bevacizumab and Bortezomib (Bevacizumab and Bortezomib)

PRO 140 (leronlimab, leronlimab (PRO 140))

mavrilimumab (mavrilimumab)

Palivizumab (Palivizumab)

ranibizumab (Lucentis, high-dose ranibizumab)

trastuzumab (Herceptin, T + trastuzumab followed by CEF + trastuzumab)

trastuzumab (Herceptin, Dose dense AC followed by T + trastuzumab)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

tanezumab (PF-04383119, PF-04383119 (tanezumab))

Bevacizumab-awwb (Bevacizumab-awwb)

Tislelizumab combined with chemotherapy (Tislelizumab combined with chemotherapy)

alemtuzumab (CAMPATH, CAMPATH (alemtuzumab))

Dostarlimab and Niraparib (Dostarlimab and Niraparib)

Rituximab, Methotrexate, and Thiotepa (R-MT, Rituximab, Methotrexate, and Thiotepa, Rituximab, Methotrexate, and Thiotepa (R-MT) Induction Followed by Etoposide and Cytarabine (EA) Consolidation)

Monoclonal antibody (Mab, Monoclonal antibody, Monoclonal antibody (Mab) sB24M)

doxorubicin HCL liposome; bevacizumab; carboplatin (doxorubicin HCL liposome; bevacizumab; carboplatin)

ARFOX + bevacizumab (arfolitixorin, arfolitixorin (ARFOX + bevacizumab))

Ramucirumab DP (Ramucirumab DP)

Erlotinib plus Bevacizumab (Erlotinib plus Bevacizumab)

Ipilimumab and Fotemustine (Ipilimumab and Fotemustine)

Pamrevlumab (Pamrevlumab)

Obexelimab (Obexelimab)

Denosumab Prefilled Syringe [Prolia] (Denosumab Prefilled Syringe [Prolia])

Seribantumab (Seribantumab)

Sindilizumab (Sindilizumab)

Sintilimab with Interleukin-2+CAPOX (Sintilimab with Interleukin-2+CAPOX)

Bevacizumab and Bortezomib (Bevacizumab and Bortezomib)

PRO 140 (leronlimab, leronlimab (PRO 140))

mavrilimumab (mavrilimumab)

Palivizumab (Palivizumab)

ranibizumab (Lucentis, high-dose ranibizumab)

trastuzumab (Herceptin, T + trastuzumab followed by CEF + trastuzumab)

trastuzumab (Herceptin, Dose dense AC followed by T + trastuzumab)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

tanezumab (PF-04383119, PF-04383119 (tanezumab))

Bevacizumab-awwb (Bevacizumab-awwb)

Tislelizumab combined with chemotherapy (Tislelizumab combined with chemotherapy)

alemtuzumab (CAMPATH, CAMPATH (alemtuzumab))

Dostarlimab and Niraparib (Dostarlimab and Niraparib)

Rituximab, Methotrexate, and Thiotepa (R-MT, Rituximab, Methotrexate, and Thiotepa, Rituximab, Methotrexate, and Thiotepa (R-MT) Induction Followed by Etoposide and Cytarabine (EA) Consolidation)

Monoclonal antibody (Mab, Monoclonal antibody, Monoclonal antibody (Mab) sB24M)

doxorubicin HCL liposome; bevacizumab; carboplatin (doxorubicin HCL liposome; bevacizumab; carboplatin)

ARFOX + bevacizumab (arfolitixorin, arfolitixorin (ARFOX + bevacizumab))

Ramucirumab DP (Ramucirumab DP)

Erlotinib plus Bevacizumab (Erlotinib plus Bevacizumab)

Ipilimumab and Fotemustine (Ipilimumab and Fotemustine)

Pamrevlumab (Pamrevlumab)

Obexelimab (Obexelimab)

Denosumab Prefilled Syringe [Prolia] (Denosumab Prefilled Syringe [Prolia])

Seribantumab (Seribantumab)